Copeptin after arginine infusion for diagnosis of diabetes insipidus
Research type
Research Study
Full title
Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus – the CARGOx Study
IRAS ID
264631
Contact name
Mirjam Chist-Crain
Contact email
Sponsor organisation
University Hospital Basel
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 2 months, 30 days
Research summary
Polyuria-polydipsia syndrome (PPS) is divided into two main entities such as central diabetes insipidus (DI) and primary polydipsia (PP). While central DI results from insufficient release of the antidiuretic hormone vasopressin (AVP), primary polydipsia is characterized by excessive water intake. The differentiation between these aetiologies is crucial, as treatment differs substantially and bears the risk of severe complications if inadequate. The study aims to compare to different tests to diagnose diabetes insipidus. The measurement of copeptin - the stable surrogate marker of AVP - after hypertonic saline infusion has been shown to be a very accurate diagnostic test. However, it needs close sodium monitoring and carries the risk of sodium overstimulation. Arginine infusion, on the other hand, is a very easy, well tolerated and safe test. There is evidence form a recent study (NCT00757276), that copeptin measurement after arginine stimulation is also a very reliable test. The aim of this study is, therefore, to compare the diagnostic accuracy of these two tests.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
19/EE/0243
Date of REC Opinion
13 Feb 2020
REC opinion
Further Information Favourable Opinion